Abstract
Ventilator-associated pneumonia (VAP) is defined as an infection of the lung parenchyma developing during mechanical ventilation, usually after at least 2 days of positive-pressure ventilation delivered via an endotracheal tube [1, 2]. This time criterion aims to exclude pneumonias caused by infectious agents already present or incubating before mechanical ventilation is started [1]. The diagnosis of VAP is usually based on clinical, radiographic, and microbiological criteria. However, the accuracy of data on the epidemiology of VAP is limited by the lack of a gold standard for its diagnosis [3]. In most reports the incidence of VAP ranges from 8% to 28% [3]. The lower incidence is reported in studies where quantitative cultures of protected specimen brushes were used to define pneumonia [4]. The incidence seems to rise from 5% for patients receiving mechanical ventilation for 1 day to 69% for those receiving mechanical ventilation for more than 30 days, with an incremental risk of pneumonia of around 1% per day [2, 5, 6]. Some authors report that, although the cumulative risk of developing VAP increases over time, the daily hazard rate decreases after 5 days of mechanical ventilation; these authors estimate the risk per day at 3% for the first 5 days of mechanical ventilation, 2% between days 5 and 10 of mechanical ventilation and 1% between days 10 and 15 of mechanical ventilation [7]. VAP is, then, a common complication of long ICU stays. Among the causative pathogens of VAP, Gram-positive strains are common and are associated with a high mortality.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Strausbaugh L (2000) Nosocomial respiratory infection. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, pp 3020–3027
Langer M, Cigada M, Mandelli M et al (1987) Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 13:342–346
Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903
Prod’hom G, Leuenberger P, Koerfer J et al (1994) Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 120:653–662
Langer M, Mosconi P, Cigada M, Mandelli M (1989) Long term respiratory support and risk of pneumonia in critically ill patients. Intensive Care Unit Group of Infection Control. Am Rev Respir Dis 140:302–305
Fagon JY, Chastre J, Domart Y et al (1989) Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 139:877–884
Cook DJ, Walter SD, Cook RJ et al (1998) Incidence of and risk factors for ventiulator-associated pneumonia in critically ill patients. Ann Intern Med 129:433–440
American Thoracic Society (1996) Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies. A consensus statement. American Thoracic Society, November 1995. Am J Respir Crit Care Med 153:1711–1725
Spencer RC (1996) Predominant pathogens found in European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 15:281–285
Kollef MH, Rello J, Cammarata SK et al (2004) Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388–394
Antonelli M, Moro ML, Capelli O et al (1994) Risk factors for early onset pneumonia in trauma patients. Chest 105:224–228
Singh N, Falestiny MN, Rogers P et al (1998) Pulmonary infiltrates in the surgical ICU: prospective assessment of predictors of etiology and mortality. Chest 114:1129–1136
Chastre J, Trouillet JL, Vuagnat A et al (1998) Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 157:1165–1172
Baraibar J, Correa H, Mariscal D et al (1997) Risk factors for infection by Acinetobacter baumanii in intubated patients with nosocomial pneumonia. Chest 112:1050–1054
Rello J, Sa-Borges M, Correa H et al (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160:608–613
Trouillet JL, Chastre J, Vuagnat A et al (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531–539
Ibrahim EH, Ward S, Sherman G, Kollef MH (2000) A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 117:1434–1442
Rello J, Ausina V, Ricart M et al (1993) Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104:1230–1235
Markowicz P, Wolff M, Djedaini K et al (2000) Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis and risk factors. ARDS Study Group Am J Respir Crit Care Med 161:1942–1948
Baker AM, Meredith JW, Haponik EF (1996) Pneumonia in intubated trauma patients. Microbiology and outcomes. Am J Respir Crit Care Med 153:343–349
Fagon JY, Chastre J, Hance AJ et al (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281–288
Craig CP, Connelly S (1984) Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Infect Control 12:233–238
Cunnion KM, Weber DJ, Broadhead WE et al (1996) Risk factors for nosocomial pneumonia: comparing adult critical care populations. Am J Respir Crit Care Med 153:158–162
Papazian L, Bregeon F, Thirion X et al (1996) Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 154:91–97
Heyland DK, Cook DJ, Griffith L et al (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in critically ill patients. The Canadian Critical Trial Group. Am J Respir Crit Care Med 159:1249–1256
Bercault N, Boulain T (2001) Mortality rate attributable to ventilator-associated nosocomial pneumonia in adult intensive care unit: a prospective case-control study. Crit Care Med 29:2303–2309
Bueno-Cavanillas A, Delgado-Rodriguez M, Lopez-Luque A et al (1994) Influence of nosocomial infection on mortality rate in an intensive care unit. Crit Care Med 22:55–60
Rello J, Torres A, Ricart M et al (1994) Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 150:1545–1549
Luna CM, Vujacich P, Niederman MS et al (1997) Impact of BAL data on therapy and outcome of ventilator-associated pneumonia. Chest 111:676–685
Ioanas M, Lode H (2004) Linezolid in VAP by MRSA: a better choice? Intensive Care Med 30:343–346
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Italia
About this paper
Cite this paper
De Gaudio, A.R., Rinaldi, S. (2007). Gram-positive ventilator-associated pneumonia: impact on mortality. In: Gullo, A. (eds) Anaesthesia, Pain, Intensive Care and Emergency A.P.I.C.E.. Springer, Milano. https://doi.org/10.1007/978-88-470-0571-6_14
Download citation
DOI: https://doi.org/10.1007/978-88-470-0571-6_14
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0570-9
Online ISBN: 978-88-470-0571-6
eBook Packages: MedicineMedicine (R0)